肝功能衰竭患者甲状腺激素与垂体激素变化的研究

肝脏 ›› 2017, Vol. 22 ›› Issue (8): 718-722.

肝功能衰竭患者甲状腺激素与垂体激素变化的研究

倪清涛,钟艳丹,蔡敏,杨永峰

210003 南京东南大学医学院传染病学研究生(倪清涛);南京市第二医院肝病科(钟艳丹,杨永峰);南京市第二医院院办(蔡敏)

收稿日期:2016-09-04 出版日期:2017-08-15 发布日期:2020-06-16
通讯作者: 杨永峰,Email: yyf1997@163.com
基金资助:
江苏省临床医学科技专项基金项目资助(编号:2013004)

Received:2016-09-04 Online:2017-08-15 Published:2020-06-16

摘要/Abstract

摘要： 目的研究肝功能衰竭(hepatic failure, HF)患者甲状腺激素和垂体激素变化及其与HF预后的相关性。方法收集2015年我院HF患者30例、慢性乙型肝炎轻中度患者58例和慢性乙型肝炎重度患者35例。比较各组患者血清甲状腺激素及垂体激素水平。结果 HF组血清T3、T4、FT3、TSH、FSH、LH水平显著低于慢性乙型肝炎轻中度组(P<0.05),HF组血清T3、T4、FT3、TSH水平显著低于慢性乙型肝炎重度组(P<0.05),HF组血清GH水平显著高于慢性乙型肝炎轻中度组GH水平(P<0.05)。HF非好转组TSH、FSH、LH明显低于好转组TSH、FSH、LH水平(P<0.05)。TSH为HF预后的保护因素。结论 HF时出现甲状腺功能减退,主要表现在T3、T4、FT3及TSH,TSH值是HF的预后指标。而垂体功能也出现异常,主要表现为TSH、FSH、LH、ACTH的下降,GH的上升,由此推测垂体功能异常可能是HF时甲状腺激素分泌异常的原因之一。

关键词: 肝功能衰竭, 甲状腺功能, 垂体功能, 激素

倪清涛,钟艳丹,蔡敏,杨永峰. 肝功能衰竭患者甲状腺激素与垂体激素变化的研究[J]. 肝脏, 2017, 22(8): 718-722.

参考文献

[1] Docter R, Krenning EP, de Jong M, et al. The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism. Clin Endocrinol(Oxf),1993,39:499-518.
[2] Liangpunsakul S,Chalasani N.Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? .J Clin Gastroenterol,2003,37:340-343.
[3] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2012年版).中华临床感染病杂志,2012,5:321-327.
[4] 中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2015年版).中国肝脏病杂志(电子版),2015,7:1-18.
[5] Anastasiou O, Sydor S, Sowa JP, et al. Higher Thyroid-stimulating hormone, triiodothyronine and thyroxine values are associated with better outcome in acute liver failure. PLoS One, 2015,10:e132189.
[6] Ray DC, Macduff A, Drummond GB, et al. Endocrine measurements in survivors and non-survivors from critical illness. Intensive Care Med, 2002,28:1301-1308.
[7] 张国超,曾龙驿,谢冬英,等.慢性乙型病毒性肝炎患者甲状腺功能的变化.中山医科大学学报, 2002, 23:125-126.
[8] Warner MH, Beckett GJ. Mechanisms behind the non-thyroidal illness syndrome: an update. J Endocrinol, 2010,205:1-13.
[9] Huang YH, Tsai MM, Lin KH.Thyroid hormone dependent regulation of target genes and their physiological significance.Chang Gung Med J, 2008,31:325-334.
[10] Fernandez V,Castillo I,Tapia G,et al.Thyroid hormone preconditioning: protection against ischemia-reperfusion liver injury in the rat. Hepatology, 2007,45:170-177.
[11] Malik R,Mellor N,Selden C,et al.Triiodothyronine enhances the regenerative capacity of the liver following partial hepatectomy. Hepatology, 2003,37:79-86.
[12] Malik R, Saich R, Rahman T, et al. During thioacetamide-induced acute liver failure, the proliferative response of hepatocytes to thyroid hormone is maintained, indicating a potential therapeutic approach to toxin-induced liver disease.Dig Dis Sci, 2006,51:2235-2241.
[13] Szilagyi A.Thyroid hormones and alcoholic liver disease. J Clin Gastroenterol, 1987,9:189-193.
[14] Wu Y,You S,Zang H, et al.Usefulness of serum thyroid-stimulation hormone (TSH) as a prognostic indicator for acute-on-chronic liver failure.Ann Hepatol, 2015,14:218-224.
[15] Oren R, Brill S, Dotan I, et al. Liver function in cirrhotic patients in the euthyroid versus the hypothyroid state. J Clin Gastroenterol, 1998,27:339-341.
[16] Zietz B, Lock G, Plach B, et al. Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis. Eur J Gastroenterol Hepatol, 2003,15:495-501.
[17] Bannister P, Handley T, Chapman C, et al. Hypogonadism in chronic liver disease: impaired release of luteinising hormone. Br Med J (Clin Res Ed), 1986,293:1191-1193.
[18] Geisthovel W. Hypothalamic-pituitary function (LH, FSH and prolactin) in males with chronic liver diseases. Z Gastroenterol, 1979,17:422-438.
[19] Cundy TF, Butler J, Pope RM,et al.Amenorrhoea in women with non-alcoholic chronic liver disease.Gut,1991,32: 202-206.
[20] Van Thiel DH,Kumar S,Gavaler JS, et al.Effect of liver transplantation on the hypothalamic-pituitary-gonadal axis of chronic alcoholic men with advanced liver disease. Alcohol Clin Exp Res, 1990,14:478-481.
[21] 李运泽, 傅宝玉, 姜若兰. 男性慢性肝病患者下丘脑-垂体-性腺轴功能的研究.中华消化杂志, 1994,14:336-338.
[22] Fede G, Spadaro L, Tomaselli T, et al. Adrenocortical dysfunction in liver disease: a systematic review. Hepatology, 2012,55:1282-1291.
[23] Cuneo RC, Hickman PE, Wallace JD, et al. Altered endogenous growth hormone secretory kinetics and diurnal GH-binding protein profiles in adults with chronic liver disease.Clin Endocrinol (Oxf), 1995,43:265-275.